BioNTech SE

LSE:0A3M Stock Report

Market Cap: US$23.4b

BioNTech Valuation

Is 0A3M undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0A3M when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 0A3M's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 0A3M's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0A3M?

Key metric: As 0A3M is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0A3M. This is calculated by dividing 0A3M's market cap by their current revenue.
What is 0A3M's PS Ratio?
PS Ratio6.3x
Sales€3.15b
Market Cap€20.12b

Price to Sales Ratio vs Peers

How does 0A3M's PS Ratio compare to its peers?

The above table shows the PS ratio for 0A3M vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average23.1x
GNS Genus
2.6x3.62%UK£1.7b
PRTC PureTech Health
63.3x-122.14%UK£303.6m
OXB Oxford Biomedica
5.1x19.75%UK£771.4m
SCLP Scancell Holdings
21.6x-73.59%UK£101.7m
0A3M BioNTech
6.3x-0.38%US$23.4b

Price-To-Sales vs Peers: 0A3M is good value based on its Price-To-Sales Ratio (6.3x) compared to the peer average (23.1x).

Price to Sales Ratio vs Industry

How does 0A3M's PS Ratio compare vs other companies in the GB Biotechs Industry?

8 CompaniesPrice / SalesEstimated GrowthMarket Cap
GNS Genus
2.6x3.62%US$2.30b
0KF3 Palatin Technologies
2.5x-40.39%US$22.39m
PBX ProBiotix Health
4.5xn/aUS$13.17m
CGNI Cardiogeni
0.9xn/aUS$8.90m
0A3M 6.3xIndustry Avg. 7.1xNo. of Companies9PS020406080100+
8 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 0A3M is good value based on its Price-To-Sales Ratio (6.3x) compared to the European Biotechs industry average (7.1x).

Price to Sales Ratio vs Fair Ratio

What is 0A3M's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0A3M PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio6.3x
Fair PS Ratio8.3x

Price-To-Sales vs Fair Ratio: 0A3M is good value based on its Price-To-Sales Ratio (6.3x) compared to the estimated Fair Price-To-Sales Ratio (8.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0A3M forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$96.23
US$137.35
+42.73%
12.67%US$173.19US$101.41n/a19
Dec ’26US$97.90
US$137.08
+40.02%
12.69%US$172.73US$101.14n/a19
Nov ’26US$103.95
US$133.88
+28.80%
12.54%US$171.04US$98.28n/a20
Oct ’26US$101.76
US$136.22
+33.86%
12.51%US$173.31US$99.71n/a20
Sep ’26US$99.75
US$137.52
+37.86%
10.95%US$172.76US$112.25n/a20
Aug ’26US$106.56
US$134.83
+26.54%
12.69%US$170.70US$109.89n/a20
Jul ’26US$108.93
US$136.71
+25.50%
15.32%US$174.90US$84.76n/a21
Jun ’26US$95.88
US$131.58
+37.24%
15.16%US$171.10US$82.21n/a22
May ’26US$101.82
US$140.11
+37.61%
12.86%US$179.33US$112.08n/a20
Apr ’26US$88.87
US$137.11
+54.29%
11.66%US$170.02US$109.56n/a21
Mar ’26US$112.82
US$139.38
+23.55%
11.81%US$172.72US$118.51n/a20
Feb ’26US$122.69
US$139.39
+13.61%
12.13%US$173.97US$118.98n/a20
Jan ’26US$111.79
US$136.02
+21.68%
10.85%US$169.75US$119.70n/a19
Dec ’25US$118.40
US$137.08
+15.77%
9.64%US$173.25US$122.28US$97.9018
Nov ’25US$110.68
US$129.04
+16.59%
17.13%US$170.67US$89.21US$103.9518
Oct ’25US$119.65
US$123.78
+3.45%
19.60%US$170.83US$84.91US$101.7618
Sep ’25US$87.21
US$110.95
+27.23%
20.43%US$174.00US$86.49US$99.7518
Aug ’25US$81.26
US$111.62
+37.36%
20.32%US$171.09US$90.14US$106.5618
Jul ’25US$79.00
US$110.58
+39.98%
20.23%US$170.43US$89.21US$108.9318
Jun ’25US$100.29
US$111.66
+11.33%
20.40%US$171.87US$90.17US$95.8818
May ’25US$87.88
US$114.10
+29.83%
20.66%US$168.57US$89.10US$101.8218
Apr ’25US$92.57
US$117.29
+26.70%
23.56%US$186.95US$89.84US$88.8718
Mar ’25US$91.15
US$126.43
+38.70%
22.51%US$187.90US$98.86US$112.8217
Feb ’25US$94.36
US$126.87
+34.45%
22.39%US$187.19US$98.49US$122.6916
Jan ’25US$106.23
US$132.42
+24.65%
21.03%US$185.60US$100.28US$111.7916
Dec ’24US$98.12
US$134.68
+37.27%
22.95%US$198.93US$99.13US$118.4017
US$137.89
Fair Value
30.2% undervalued intrinsic discount
19
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/09 01:37
End of Day Share Price 2025/12/09 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BioNTech SE is covered by 34 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Harry GillisBerenberg
Zhiqiang ShuBerenberg
Evan SeigermanBMO Capital Markets Equity Research